MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517089622 A) filed by Joint-Stock Company Generium, Volginskiy, Russia, on Sept. 19, for 'pharmaceutical composition and method for the prophylaxis and treatment of a lysosomal enzyme deficiency in a subject with mucopolysaccharidosis type ii.'
Inventor(s) include Shukurov, Rakhim Rakhmankulyyevich; Reshetnik, Elizaveta Vyacheslavovna; Khamitov, Ravil Avgatovich; and Shuster, Aleksandr Mikhailovich.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The invention relates to the field of biotechnology, and more particularly to a pharmaceutical composition and a method for the prophylaxis and treatment of a lysosomal enzyme deficiency in a subject, which can be used in medicine. The present invention relates to an HIR-Fab-IDS compound that can be used for the prophylaxis or treatment of a lysosomal enzyme deficiency in a subject suffering from a lysosomal storage disease in the form of mucopolysaccharidosis type II (MPS II), wherein at least one dose of said HIR-Fab-IDS compound is administered to the subject in an amount of from 1 to 12 mg/kg, and further relates to a pharmaceutical composition for use in the prophylaxis or treatment of a lysosomal enzyme deficiency in a subject with the lysosomal storage disease MPS II, wherein the composition contains said HIR-Fab-IDS compound, as well as to a method for the prophylaxis or treatment of a lysosomal enzyme deficiency in a subject with the lysosomal storage disease MPS II, which includes administering at least one dose of said HIR-Fab-IDS compound to the patient."
The patent application was internationally filed on Feb. 20, 2024, under International application No.PCT/RU2024/050043.
Disclaimer: Curated by HT Syndication.
